UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect [Yahoo! Finance]
Arcellx, Inc. (ACLX)
Company Research
Source: Yahoo! Finance
Arcellx with a Buy rating and $100 price target as the firm assumed coverage on 22 small-to-mid cap biotech names. Contending that biotech fundamentals are now inflecting after a rough period, UBS expects investor confidence to recover and sees this positioning the sector for strong performance in 2026. Earlier on December 22, Wells Fargo initiated coverage of Arcellx Inc. (NASDAQ:ACLX) with an Overweight rating and a $100 price target, identifying the company's anito-cel as a future pillar in the treatment of multiple myeloma. Photo by Robb Miller on Unsplash Wells Fargo contends that anito-cel is positioned to capture a majority of the BCMA CAR-T market for fourth-line multiple myeloma due to its attractive efficacy and safety profile, with rapid uptake expected upon its projected launch in 2026. Furthermore, the firm remains optimistic about Arcellx's broader opportunities within the CAR-T space, notwithstanding recent data from industry competitors. Arcellx Inc. (NASDAQ:AC
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- Arcellx (NASDAQ:ACLX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings [Yahoo! Finance]Yahoo! Finance
- Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem MeetingsBusiness Wire
- Arcellx (NASDAQ:ACLX) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.MarketBeat
- Arcellx (NASDAQ:ACLX) was given a new $100.00 price target on by analysts at UBS Group AG.MarketBeat
ACLX
Earnings
- 11/5/25 - Miss
ACLX
Sec Filings
- 1/20/26 - Form 4
- 1/20/26 - Form 144
- 1/14/26 - Form 144
- ACLX's page on the SEC website